Posters
- Resources
- Posters
Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.
Clinical Flow Cytometry
Hematological Malignancies
Humanized Models
Lumin Acuity
Solid Tumor PDX Models
An Integrated Platform for Antibody-Drug Conjugate Discovery and Development - Tumor Models San Francisco 2025
A Novel Gene Signature predicting fibroblast composition in the TME allows for an improved selection of PDX models for preclinical studies - AACR 2024
Raptamer-Drug Conjugates as Molecularly Targets Cancer Therapeutics - AACR 2023
Combining Multiomics and Histological Assessment to Identify Patient-derived Xenograft Models of Invasive Lobular Carcinoma - San Antonio Breast Cancer Symposium 2022
TumorGraft3D & Co-Culture Platforms
Bioluminescent 3D Tumors with Immune Cell Co-culture for High Throughput Screening (HTS) - AACR 2024
A Novel 3D Co-Culture Platform for Patient-Specific Immune-Oncology Treatment - AACR 2024
An Innovative PDX and Patient-derived 3D Platform for Improved Translatability of New Medical Entities - AACR 2024
A Novel TumorGraft3D immune co-culture platform for high throughput immune-oncology screening - SITC 2023
Identification of synergistic combination of molecular targeted agents and chemotherapy using TumorGraft3D and Lumin platform - Tumor Models Boston 2023
Unique 3D Organoids Autologous TIL Co-Culture Platform Enables High Throughput Immune-Oncology Drug Response Studies - AACR 2021
Development of a 3D Organoid Autologous TIL Co-Culture Platform for High Throughput Immuno-Oncology Studies - SITC 2020